ArticleBioinformation2026
CA 15.3-driven F-18-FDG PET-CT for early detection of breast cancer recurrence: Diagnostic accuracy and clinical impact.
Article in Bioinformation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An isolated rise in serum tumor marker CA 15.3 during post-treatment surveillance of breast cancer patients represents a notable diagnostic challenge. In many such cases, conventional imaging modalities fail to identify occult sites of early disease recurrence. Consequently, this diagnostic limitation may result in a delay in timely and appropriate clinical management. This study aimed to evaluate the diagnostic accuracy of whole-body F-18-FDG PET-CT imaging in early localization of breast cancer recurrence in patients with elevated CA 15.3 levels. Hence, the study included 50 routine breast cancer patients at Guru Gobind Singh Medical College & Hospital, Faridkot, who showed signs of disease relapse and were monitored for signs of recurrence, based on rising tumor markers. This study found a significant correlation between elevated CA 15.3 levels and PET-CT-detected recurrences in patients. Bone recurrences had the highest combined CA 15.3 levels. PET-CT findings altered clinical management in 80% of cases, with 28/40 receiving targeted radiotherapy, 9/50 initiating new systemic therapy and 3/40 starting with endocrine therapy. PET-CT is essential for the early detection of occult recurrences in breast cancer patients with elevated CA 15.3 levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.